Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
← catalyst calendarNCT07061626 · readout ≤ 224 d
Sponsored by Plus Therapeutics (industry) · PSTV — their whole pipeline →. With Ann & Robert H Lurie Children's Hospital of Chicago.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
56estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2025 | estimated | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ependymoma
- High Grade Gliomas
Intervention
- Drug: Rhenium-186 Nanoliposome
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD)
measured 28 days
Overall Response Rate (ORR) by RANO in Ependymoma
measured 90 days
Progression-Free Suvival at 12 months (PFS12) in HGG
measured 12 months
Permalink · PSTV's whole pipeline · Catalyst calendar · Every registered study · What changed